Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Didac Ramal"'
Autor:
Max Hardy-Werbin, José Maria Maiques, Marcos Busto, Isabel Cirera, Alfons Aguirre, Nieves Garcia-Gisbert, Flavio Zuccarino, Santiago Carbullanca, Luis Alexander Del Carpio, Didac Ramal, Ángel Gayete, Jordi Martínez-Roldan, Albert Marquez-Colome, Beatriz Bellosillo, Joan Gibert
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract The rapid spread of the severe acute respiratory syndrome coronavirus 2 led to a global overextension of healthcare. Both Chest X-rays (CXR) and blood test have been demonstrated to have predictive value on Coronavirus Disease 2019 (COVID-19
Externí odkaz:
https://doaj.org/article/3ae2a8c98443459290162cd00ba2c0fd
Autor:
Pedro Rocha, MD, Didac Ramal, MD, Enric Ripoll, MD, Laura Moliner, MD, Alex Corbera, MD, Max Hardy-Werbin, MD, PhD, Mayra Orrillo, MD, Álvaro Taus, MD, Flavio Zuccarino, MD, Joan Gibert, Júlia Perera-Bel, David Casadevall, MD, PhD, Edurne Arriola, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100115- (2021)
Introduction: Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSCLC has been reported in multiple studies. However, inconsistent results in incidence and survival outcomes within studies, together with different ass
Externí odkaz:
https://doaj.org/article/aa5ac2c35017431287482d1faf250d70
Autor:
M. Hardy-Werbin, Álvaro Taus, Didac Ramal, Alex Corbera, Pedro Rocha, Enric Ripoll, Mayra Orrillo, Edurne Arriola, L. Moliner, Joan Gibert, David Casadevall, Júlia Perera-Bel, Flavio Zuccarino
Publikováno v:
JTO Clinical and Research Reports
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100115-(2021)
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100115-(2021)
Introduction Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSCLC has been reported in multiple studies. However, inconsistent results in incidence and survival outcomes within studies, together with different asse